Navigation Links
Oral drug may improve survival in men with metastatic prostate cancer
Date:11/19/2013

DURHAM, N.C. An investigational prostate cancer treatment slows the disease's progression and may increase survival, especially among men whose cancer has spread to the bones, according an analysis led by the Duke Cancer Institute.

The study, published on Nov. 19, 2013, in the journal Clinical Cancer Research, adds long-term survival and safety data for the drug tasquinimod, a new candidate for treating advanced and recurrent prostate cancer.

"While all subgroups in the clinical trial benefited from tasquinimod, those whose cancer metastasized to their bones had the greatest benefit in terms of delaying the time from the start of treatment to when the cancer progressed," said lead author Andrew J. Armstrong, M.D., ScM, associate professor of medicine at the Duke Cancer Institute. "This group of men also seemed to have a longer survival benefit when we followed them over several years."

Tasquinimod, a drug in development by Active Biotech in partnership with Ipsen, is an oral therapy that activates the body's immune system to fight cancer. Its mechanism is not fully understood, but it appears to affect the function of myeloid-derived suppressor cells, which are found in increased numbers in cancer patients. Tasquinimod is also known to block tumor blood vessel growth, a process termed angiogenesis.

New treatments approved in recent years have given physicians and patients additional options to fight prostate cancer, but the therapies typically only extend patients' lives by three to five months. New drugs that increase survival without serious side effects are still needed.

In this phase II clinical trial, funded by Active Biotech, researchers studied the use of tasquinimod among men with metastatic castration-resistant prostate cancer, an advanced form of the disease that does not respond to hormonal therapy. The study enrolled 201 men who were followed for approximately three years, with 134 randomly assigned to receive tasquinimod and 67 given placebo.

The researchers measured patients' overall survival, whether their cancer progressed, and the drug's safety and tolerability. They also conducted studies of biomarkers to better understand how tasquinimod stimulates the immune system.

Armstrong and his colleagues found that men taking tasquinimod saw no cancer progression for an average of 7.6 months, compared with 3.3 months for placebo. Men whose cancer had already metastasized to their bones and took tasquinimod remained progression-free for even longer 8.8 months, compared with 3.4 months for placebo.

"By delaying the onset of symptoms or growth of metastatic tumors, tasquinimod may allow men to put off other treatments, such as chemotherapy, and maintain a high quality of life," Armstrong said. "That's an important goal for many patients and providers."

Men taking tasquinimod survived 33.4 months on average, versus 30.4 months with placebo. However, those whose cancer had already metastasized to their bones survived an average of 34.2 months, compared with 27.1 months for placebo, a seven-month difference. This improvement in survival with tasquinimod persisted when statistical adjustments were made for other factors such as PSA level, PSA doubling time, lactate dehydrogenase (LDH) levels, and the presence of anemia, each of which were important prognostic factors.

The researchers also identified certain predictors of who would benefit most from tasquinimod, such as lower baseline PSA levels or other biomarkers.

The treatment was considered safe with low to moderate side effects, which included mild gastrointestinal issues, muscle and joint pains, and fatigue.

Based on results from the phase II clinical trial, tasquinimod is now being evaluated in an international phase III trial focusing on men whose prostate cancer has spread to their bones and become resistant to hormonal therapies.

"We still need to do more research to understand the efficacy and mechanism of action of tasquinimod, who benefits the most from it, how it fits into a treatment regimen, and how it could be used in combination with other therapies," Armstrong said. "In addition, tasquinimod is not a prostate cancer-specific drug. If the phase III trial shows that tasquinimod is effective and safe, this opens the door for evaluating the immunotherapy in other cancers."


'/>"/>

Contact: Rachel Harrison
rachel.harrison@duke.edu
919-419-5069
Duke University Medical Center
Source:Eurekalert

Related medicine news :

1. Clinical insight improves treatment with new lung cancer drug
2. Improved Stem Cell Line May Avoid Tumor Risk: Study
3. Normalizing tumor blood vessels improves delivery of only the smallest nanomedicines
4. Exercise improves quality of life during breast cancer treatment
5. IU, Regenstrief automated system aims to improve child health
6. Swallowing exercises linked with short-term improvement among patients with head and neck cancer
7. MU receives national award for using mind-body approach to improve health
8. Feelings of immaturity accompany alcohol misuse into adulthood; discovery could improve treatments
9. Awards celebrate clinical research that can improve health and alleviate suffering
10. Naturopathic care can improve blood sugar, mood in diabetes
11. Early treatment improves outcomes in rare, often undiagnosed form of encephalitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... June 27, 2016 , ... Quality metrics are proliferating ... many ways they remain in the eye of the beholder, according to experts who ... of The American Journal of Managed Care. For the full issue, click here ...
(Date:6/26/2016)... Orion, Clarkston, Michigan (PRWEB) , ... June 26, ... ... with respect to fertility once they have been diagnosed with endometriosis. These women ... intercourse but they also require a comprehensive approach that can help for preservation ...
(Date:6/25/2016)... ... ... First Choice Emergency Room , the largest network of independent freestanding emergency ... its new Mesquite-Samuell Farm facility. , “We are pleased to announce Dr. Ogunleye ... M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , Dr. Ogunleye ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article ... are unfamiliar with. The article goes on to state that individuals are now more ... these less common operations such as calf and cheek reduction. The Los Angeles area ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, P.A. announced ... attorneys chosen by their peers for this recognition are considered among the top 2 ... received special honors as members of this year’s Legal Elite Hall of Fame: ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016 ... Market by Type (Standard Pen Needles, Safety Pen Needles), ... (Insulin, GLP-1, Growth Hormone), Mode of Purchase (Retail, Non-Retail) ... MarketsandMarkets, This report studies the market for the forecast ... to reach USD 2.81 Billion by 2021 from USD ...
(Date:6/23/2016)... , June 23, 2016  MedSource announced ... as its e-clinical software solution of choice.  This ... best possible value to their clients by offering ... The preferred relationship establishes nowEDC as the EDC ... for MedSource,s full-service clients.  "nowEDC has long been ...
(Date:6/23/2016)... a startling report released today, National Safety Council research ... proven plan to eliminate prescription opioid overdoses. Prescription Nation ... tackling the worst drug crisis in recorded U.S. history, assigned a ... , New Mexico , Tennessee ... failing states, three – Michigan , ...
Breaking Medicine Technology: